Phase I/II Open Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Patients With Refractory/Relapsed CD30 Lymphoma.
Phase of Trial: Phase I/II
Latest Information Update: 29 May 2013
At a glance
- Drugs Iratumumab (Primary)
- Indications B cell lymphoma; Hodgkin's disease; T cell lymphoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 17 Apr 2008 Status change from in progress to completed according to a Medarex media release.
- 16 Apr 2008 Results were reported at AACR 2008.